Bioxytran (BIXT) EBITDA Margin (2010 - 2018)
Bioxytran (BIXT) posted EBITDA Margin of 1.35% for Q2 2018, up 73.09% sequentially from 5.03% in Q1 2018, and up 65346.0% YoY from N/an in Q2 2017.
Bioxytran (BIXT) EBITDA Margin (2010 - 2018) Analysis & Trends
Bioxytran has reported EBITDA Margin for 9 years, with the latest figure at 1.35% in Q2 2018.
- Quarterly EBITDA Margin rose 65346.0% year-over-year to 1.35% in Q2 2018, while the trailing twelve-month figure through Jun 2018 was 20.54% (up 17142.0% YoY) and the FY2017 annual result came in at 162.55%, up 10978.0% from the prior year.
- EBITDA Margin improved to 1.35% in Q2 2018 per BIXT's latest filing, from 5.03% in the prior quarter.
- Over five years, EBITDA Margin peaked at 1456.58% in Q4 2014 and troughed at 3222.32% in Q2 2015.
- A 5-year average of 446.82% and a median of 103.97% in 2014 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2015 and 2016: EBITDA Margin tumbled 307393 bps in 2015, then surged 296459 bps in 2016.
- Over 5 years, EBITDA Margin stood at 1456.58% in 2014, then tumbled by 100 bps to 5.45% in 2015, then surged by 4225 bps to 235.79% in 2016, then tumbled by 214 bps to 268.45% in 2017, then soared by 99 bps to 1.35% in 2018.
- According to Business Quant data, EBITDA Margin over the past three periods registered 1.35%, 5.03%, and 268.45% for Q2 2018, Q1 2018, and Q4 2017 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.75% |
| 10 | Bioxytran | 2.52 Mn | 2.27 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2018 | -1.35% |
| Mar 31, 2018 | -5.03% |
| Dec 31, 2017 | -268.45% |
| Sep 30, 2017 | 45.40% |
| Jun 30, 2017 | -654.81% |
| Mar 31, 2017 | -842.33% |
| Dec 31, 2016 | 235.79% |
| Sep 30, 2016 | -209.65% |
| Jun 30, 2016 | -257.73% |
| Mar 31, 2016 | -1,437.24% |
| Dec 31, 2015 | 5.45% |
| Sep 30, 2015 | -25.41% |
| Jun 30, 2015 | -3,222.32% |
| Mar 31, 2015 | -59.54% |
| Dec 31, 2014 | 1,456.58% |
| Sep 30, 2014 | -2,685.23% |
| Jun 30, 2014 | -148.40% |
| Mar 31, 2014 | 31.56% |
| Dec 31, 2013 | -62.56% |
| Sep 30, 2013 | -493.85% |